WO1992003475A1 - Enterovirus peptides - Google Patents
Enterovirus peptides Download PDFInfo
- Publication number
- WO1992003475A1 WO1992003475A1 PCT/SE1991/000542 SE9100542W WO9203475A1 WO 1992003475 A1 WO1992003475 A1 WO 1992003475A1 SE 9100542 W SE9100542 W SE 9100542W WO 9203475 A1 WO9203475 A1 WO 9203475A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- thr
- val
- ala
- gly
- amino acid
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 66
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 44
- 241000709661 Enterovirus Species 0.000 title claims description 13
- 239000000427 antigen Substances 0.000 claims abstract description 51
- 102000036639 antigens Human genes 0.000 claims abstract description 51
- 108091007433 antigens Proteins 0.000 claims abstract description 51
- 241000709664 Picornaviridae Species 0.000 claims abstract description 40
- 241000710831 Flavivirus Species 0.000 claims abstract description 39
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims abstract description 32
- 201000010099 disease Diseases 0.000 claims abstract description 32
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 32
- 229960005486 vaccine Drugs 0.000 claims abstract description 15
- 208000015181 infectious disease Diseases 0.000 claims abstract description 13
- 238000003745 diagnosis Methods 0.000 claims description 27
- 210000002966 serum Anatomy 0.000 claims description 24
- 238000003018 immunoassay Methods 0.000 claims description 19
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 16
- 125000000539 amino acid group Chemical group 0.000 claims description 16
- 239000000126 substance Substances 0.000 claims description 16
- 230000001154 acute effect Effects 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 239000011347 resin Substances 0.000 claims description 8
- 229920005989 resin Polymers 0.000 claims description 8
- 238000003556 assay Methods 0.000 claims description 7
- 230000000405 serological effect Effects 0.000 claims description 7
- 238000012360 testing method Methods 0.000 claims description 7
- 208000005155 Picornaviridae Infections Diseases 0.000 claims description 6
- 230000000890 antigenic effect Effects 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 241000991587 Enterovirus C Species 0.000 claims description 5
- 206010054261 Flavivirus infection Diseases 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- 238000003127 radioimmunoassay Methods 0.000 claims description 4
- 241000709687 Coxsackievirus Species 0.000 claims description 3
- 241000725619 Dengue virus Species 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 238000003119 immunoblot Methods 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- 241000710842 Japanese encephalitis virus Species 0.000 claims description 2
- 241000710772 Yellow fever virus Species 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000003053 immunization Effects 0.000 claims description 2
- 238000002372 labelling Methods 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- -1 microplate Polymers 0.000 claims description 2
- 231100000252 nontoxic Toxicity 0.000 claims description 2
- 230000003000 nontoxic effect Effects 0.000 claims description 2
- 229940051021 yellow-fever virus Drugs 0.000 claims description 2
- 238000001514 detection method Methods 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- LQRJAEQXMSMEDP-XCHBZYMASA-N peptide a Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)NCCCC[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)C(\NC(=O)[C@@H](CCCCN)NC(=O)CNC(C)=O)=C/C=1C=CC=CC=1)C(N)=O)C(=O)C(\NC(=O)[C@@H](CCCCN)NC(=O)CNC(C)=O)=C\C1=CC=CC=C1 LQRJAEQXMSMEDP-XCHBZYMASA-N 0.000 claims 1
- 102100029905 DNA polymerase epsilon subunit 3 Human genes 0.000 description 27
- 101710104359 F protein Proteins 0.000 description 27
- 150000001413 amino acids Chemical class 0.000 description 13
- 230000009257 reactivity Effects 0.000 description 9
- 101710197658 Capsid protein VP1 Proteins 0.000 description 8
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 8
- 241000700605 Viruses Species 0.000 description 8
- 101710132601 Capsid protein Proteins 0.000 description 7
- 101710118046 RNA-directed RNA polymerase Proteins 0.000 description 7
- 101710108545 Viral protein 1 Proteins 0.000 description 7
- 238000000034 method Methods 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 5
- 208000006740 Aseptic Meningitis Diseases 0.000 description 4
- 206010027201 Meningitis aseptic Diseases 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- 206010014909 Enterovirus infection Diseases 0.000 description 3
- 206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 description 3
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 3
- 241001144416 Picornavirales Species 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241001466953 Echovirus Species 0.000 description 2
- 101710091045 Envelope protein Proteins 0.000 description 2
- 108700010908 HIV-1 proteins Proteins 0.000 description 2
- 241000709721 Hepatovirus A Species 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 208000000474 Poliomyelitis Diseases 0.000 description 2
- 101710188315 Protein X Proteins 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 102100021696 Syncytin-1 Human genes 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 241000238876 Acari Species 0.000 description 1
- 108091032955 Bacterial small RNA Proteins 0.000 description 1
- 235000011297 Brassica napobrassica Nutrition 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241000709677 Coxsackievirus B1 Species 0.000 description 1
- 241000256113 Culicidae Species 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 241000710829 Dengue virus group Species 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 206010057199 Flaviviral infections Diseases 0.000 description 1
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 206010061308 Neonatal infection Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 238000012850 discrimination method Methods 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 208000012022 enterovirus infectious disease Diseases 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 108010023958 glycyl-threonyl-alanyl-methionyl-arginyl-isoleucyl-leucyl-glycyl-glycyl-valyl-isoleucine Proteins 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000012070 reactive reagent Substances 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32311—Enterovirus
- C12N2770/32322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32711—Rhinovirus
- C12N2770/32722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- antigenic parts thereof as used herein means antigenic parts in the essential amino acid sequence between R 1 and R 2 in the peptides according to the present invention.
- the invention can be considered to belong to a previously unknown class of sequences having a common structure and function.
- the peptides can be used for diagnosing diseases caused by both picornavirus and flavivirus, the peptides can, because of their common origin, structure and function, however with a certain, appropriate
Abstract
Peptides and a diagnostic antigen containing one of said peptides and having the ability to detect antibodies against at least one type of picornavirus and flavivirus are described. The use of said diagnostic antigen for diagnosing infections caused by picornavirus and/or flavivirus and for discriminating between false and true diagnosed HIV-1 p17 positive sera is also described, as well as vaccines against diseases caused by picornaviruses and/or flaviviruses.
Description
EMTEROVTRUS PEPTIDES
The present invention relates to new peptides, to a diagnostic antigen, to the use of said diagnostic antigen in immunoassays and to a vaccine containing said diagnostic antigen.
Background art
Picornaviruses are a family of small RNA viruses which are responsible for a variety of diseases in humans and animals. The diseases may be severe, like poliomyelitis (caused by polioviruses types 1, 2, and 3), hepatitis (caused by hepatitis A virus) and generalized neonatal enterovirus infection (often caused by Coxsackie and ECHO viruses), as well as mild, like the common cold (caused by rhinoviruses). Picornaviruses then are
significant pathogens, and the diagnosis of infections caused by them is an important medical task. A clinical virological laboratory receives many samples every year for diagnosis of picornavirus infections. The picornavirus family is divided into the enterovirus, rhinovirus and hepatitis A subfamilies. Among these, the enteroviruses and hepatitis A viruses are the ones where a diagnosis is most often sought. The enteroviruses are further divided into polio-, Coxsackie A, Coxsackie B and ECHO viruses on the basis of their pathogenicity in mice. The enteroviral disease where a diagnosis is most often required is aseptic meningitis, but myocarditis, encephalitis, generalized neonatal infection and hand-, foot and mouth disease also constitute rather frequent clinical problems.
Flavivirus is another virus family which e.g. causes yellow fever and encephalitis. These diseases are spread by mosquitos and ticks and constitute a major worldwide problem. The Dengueviruses and TBE-virus are types of flaviviruses.
There is currently no therapy for these infections, so the diagnosis of picornavirus and flavivirus infections serves mostly to exclude other diseases or to give
epidemiological information.
The diagnosis of a picornavirus infection can be made either by virus isolation or by serology. In the latter case, for enteroviruses, a serum sample taken early in the course of the infection (an acute phase serum) and a serum taken 1-3 weeks later (a convalescent phase serum) are analyzed with an antibody assay, most commonly a complement fixation assay (see e.g. Sever JL. Application of a microtechnique to viral serological investigations.
J. Immunol, 88:320-329). The antigen then is a purified or semipurified preparation from picornavirus-infected cells. If non-heat-treated virus antigens are used, a relatively type-specific antibody assay is obtained. If a heattreated viral antigen is used, a more group-specific assay is obtained. Presumably, the virus undergoes a conformational change upon heating, exposing group-specific antigenie determinants. The conformational change mostly seems to involve the N-terminus of VP1 [Fricks CE, Hogle JM. Cell-induced conformational change in poliovirus: Externalization of the amino terminus of VP1 is responsible for liposome binding. J. Virol. 64:193-1945 (1990)1. There are some indications that antibodies to this portion of VP1 can influence the course of infection [Chow M, Yabrov R, Bittle J, Hogle JM, Baltimore D. Synthetic peptides from four separate regions of the poliovirus capsid protein VP1 induce neutralizing antibodies. Proc Natl Acad Sci USA 82:910-914 (1985)1, this making it interesting also as a candidate for vaccination purposes. For flaviviruses, a variety of serological techniques exist, all of which however have great limitations due to lack of sensitivity or specificity.
Thus, there is a need for a means for a more exact diagnosis of diseases caused by picornavirus and flavi
virus, which could further specify and facilitate the treatment of the disease concerned.
Further, there is a need for vaccines for different diseases caused by picornavirus and flavivirus.
One object of the present invention is to provide new peptides which can be used as a diagnostic antigen in immunoassays.
Another object of the present invention is to use a diagnostic antigen for more specific diagnosing of diseases or infections caused by picornavirus and/or flavivirus and/or discriminating between false and true diagnosed HIV-1 positive sera.
Still another object of the present invention is to provide a vaccine based on said peptides against diseases or infections caused by picornavirus and/or flavivirus.
All these objects are achieved by the present invention.
Description of the invention
In one aspect, the present invention relates to peptides of the formula:
a) H-X-R1-Ala-Y1-Glu-Thr-Gly-His-Thr-Ser-Gln-Val- R2-X-Z, wherein Y1 is Ala or Val,
b) H-X-R1-Ala-Y1-Glu-Thr-Gly-Ala-Thr-Asn-Pro-Leu- R2-X-Z, wherein Y1 is Ala or Val,
c) H-X-R1-Ala-Ala-Glu-Thr-Gly-His-Thr-Ser-Y1-Val- R 2-X-Z, wherein Y1 is Ser or Asn,
d) H-X-R1-Y1-Asp-Thr-Gly-His-Gly-Thr-Val-Y2-R2-X-Z, wherein Y 1 is Ala or Thr and Y2 is Val or Ile, e) H-X-R1-Thr-Asp-Y1-Gly-His-Asp-Thr-Val-Y2-R2-X-Z, wherein Y1 is Ser or Thr and Y2 is Ile or Val, and
f) H-X-R1-Ala-Glu-Thr-Gln-Y1-Gly-Thr-Y2-Val-R2-X-Z, wherein Y 1 is His or Tyr and Y2 is Ile or Thr, in which one X represents a chemical bond and the other X represents a chemical bond or a coupling-facilitating amino acid sequence, R 1 and R2 represent optional amino acid residues, wherein R 1 and R2 together represent at
most 25 amino acid residues, and Z represents -NH2 or -OH. In another aspect, the present invention relates to a diagnostic antigen having the ability to detect antibodies against at least one type of picornavirus and flavivirus in sera, and/or having the ability of binding to antibodies with a binding affinity for compounds containing an amino acid sequence corresponding to an epitope or cluster of epitopes of HIV-1 p17, wherein said antigen mainly comprises an antigen selected from the peptides according to claim 1 and antigenic parts thereof.
In still another aspect, the present invention relates to the use of at least one diagnostic antigen for diagnosis of infections caused by picornaviruses and/or flaviviruses, wherein the diagnostic antigen or antigens having the ability to detect antibodies against at least one type of picornavirus and flavivirus are added to a serum from a subject suspected to have a recent or previous picornavirus and/or flavivirus infection, and possible antigen/ antibody complexes formed are detected using an immunoassay, the diagnosis of said recent or previous infection(s) caused by picornaviruses and/or flaviviruses being established based either upon demonstration of antibodies in a single serum or upon a comparison of the amounts of antibodies detected in both acute and convalescent phase sera, and if said amount in the convalescent phase serum is significantly larger than in the acute phase serum, the subject donating the serum suffers or has suffered from a picorna- and/or flavivirus infection, wherein the antigen containing the peptides
a) H-X-R1-Ala-Y1-Glu-Thr-Gly-His-Thr-Ser-Gln-Val-R2-X-Z, wherein Y1 is Ala or Val, is primarily used for diagnosis of diseases caused by Coxsackievirus, b) H-X-R1-Ala-Y1-Glu-Thr-Gly-Ala-Thr-Asn-Pro-Leu-R2-X-Z, wherein Y1 is Ala or Val, is primarily used for diagnosis of diseases caused by poliovirus,
c) H-X-R1-Ala-Ala-Glu-Thr-Gly-His-Thr-Ser-Y1-Val-R2-X-Z, wherein Y1 is Ser or Asn, is primarily used for
diagnosis of deseases caused by rhinovirus,
d) H-X-R1-Y1-Asp-Thr-Gly-His-Gly-Thr-Val-Y2-R2-X-Z,
wherein Y 1 is Ala or Thr and Y2 is Val or Ile, is primarily used for diagnosis of diseases caused by yellow fever virus and Japanese encephalitis virus, e) H-X-R1-Thr-Asp-Y1-Gly-His-Asp-Thr-Val-Y2-R2-X-Z,
wherein Y 1 is Ser or Thr and Y2 is Ile or Val, is primarily used for diagnosis of diseases caused by
TBE-virus,
and
f) H-X-R1-Ala-Glu-Thr-Gln-Y1-Gly-Thr-Y2-Val-R2-X-Z,
wherein Y 1 is His or Tyr and Y2 is Ile or Thr, is primarily used for diagnosis of diseases caused by
Dengue- and rhinovirus,
in which one X represents a chemical bond and the other X represents a chemical bond or a coupling-facilitating amino acid sequence, R 1 and R2 represent optional amino acid residues, wherein R 1 and R2 together represent at most 25 amino acid residues, and Z represents -NH- or -OH.
In still another aspect, the present invention relates to the use of a diagnostic antigen for discriminating between a false and true diagnosed HIV-1 positive serum sample, which has first been diagnosed as positive in a standard HIV-1 antibody screening EIA test and then found to exhibit a p17 pattern of serological activity in an electrophoretic immunoblot assay, wherein at least one diagnostic antigen having the ability of binding to antibodies which have a binding affinity for compounds containing an amino acid sequence corresponding to an epitope or cluster of epitopes of HIV-1 p17, optionally coupled to a carrier, is added to said serum sample, and possible antigen/antibody complexes formed are detected using an immunoassay, the discrimination being established such that said serum sample is false HIV-1 positive if said complexes are detected, and true HIV-1 positive if said complexes are not detected.
In still another aspect, the present invention relates to a vaccine composition which comprises as an immunizing component at least one picornavirus and/or flavivirus antigen selected from at least one of the peptides above.
Other characteristics and features of the present invention appear from the attached claims.
In the peptides according to the present invention, one X represents a chemical bond and the other X represents a chemical bond or a coupling-facilitating sequence of at least 4, and preferably 8, particular amino acid residues, which are all chosen from the group consisting of -Thr- and -Ser-. When X is an amino acid sequence, it can be located either in the C- or N-terminus of the peptides but not in both ends at the same time. If it is for example located in the C-terminus, X in the N-terminus corresponds to a chemical bond and vice versa. However, X can be a bond at both ends of the peptide according to the present invention. The amino acid sequence acts as a coupling-facilitating spacer, which permits proper binding to the carrier to which the peptides according to the present invention will be bound during the discrimination method. The sequence X should not be an amino acid
sequence which adversely affects the result of the diagnosis method. Accordingly, it should not have too high a charge or be too hydrophobiσ and it should not disturb the conformation of the peptides. The amino acids threonine and serine also fulfill these requirements particularily well, and any one of the amino acids in said sequence X can be threonine or serine. The number of amino acids in this spacer sequence should be at least 4, but in a preferred embodiment according to the present invention 8 amino acids are used.
R 1 and R2 are optional amino acid residues and together represent at most 25 amino acid residues, preferably 20. Further, this means that one or both of R 1 and R2 can be a chemical bond, i.e. contain no amino acids. If R1
is a sequence containing e.g. 25 amino acid residues, R2 must be a chemical bond and vice versa.
The expression "and antigenic parts thereof as used herein means antigenic parts in the essential amino acid sequence between R 1 and R2 in the peptides according to the present invention.
The polypeptides according to the present invention can be bound via the amino acid sequence X to a carrier by physical/chemical interaction, as for example covalent binding, ionic binding, hydrogen binding or hydrophobic binding. Examples of covalent binding are ester, ether and disulfide binding.
The expression "carrier" as used herein should be interpreted broadly, and it may be any material which is compatible with and not adversely affects the method according to the present invention, for example resins, microplates, plastic surfaces, gels, matrixes etc.
The expression "epitope" as used herein means antigenic or immunogenic determinant and relates to a specific part of a structure of an antigen inducing an immuno response, and the antibodies produced are directed against this part.
The immunoassay method according to the present invention can be an enzyme immunoassay (EIA), radioimmunoassay (RIA), immunoassay involving metal labelling, fluorescence immunoassay (FIA) or an immunoassay in which the peptide is soluble and inhibits another reaction.
The vaccine composition according to the present invention comprises at least one picornavirus and/or flavivirus antigen selected from the peptides according to the present invention together with a non-toxic pharmaceutically acceptable carrier and/or a diluent in an amount effective to protect a subject from diseases caused by picornavirus and/or flavivirus.
Further, the vaccine composition comprises an antigen adjuvant in an amount which together with an amount of said picornavirus and/or flavivirus antigen(s) is effec
tive to protect a subject from diseases caused by picornaviruses and/or flaviviruses.
Further, the vaccine composition additionally comprises one or more buffers and/or preservatives.
The peptides according to the invention are derived from sequences which are exposed upon heat inactivation of picornavirus or are situated on the other envelope proteins of flavivirus particles, and they are able to detect broadly cross-reactive picornavirus and flavivirus antibodies. This makes it possible to diagnose picornaviral and/or flaviviral infections or diseases by the use of only one or a few peptides from the highly conserved antigenically active picornaviral and flaviviral sequence.
The location of this sequence on the envelope protein, its pronounced evolutionary conservation in flaviviruses and the proven antigeniσity of analogous sequences in picornaviruses make this sequence especially accessible for antibodies suitable for diagnostic and immunisation purposes.
The peptide sequences according to the present invention can be said to derive from a common basic structure which can be expressed as the consensus sequence
aaDTGHxLxV where the capital letters relate to amino acids of strong or complete conservation, the small letters relate to amino acids present in more than half of the cases, and x relates to any amino acid. This common basic structure has been discovered on one and the same occasion and has been described in an article by Blomberg &
Medstrand in New Biologist 2:1044-1046 (1990). In
picornavirus, this sequence is situated at one site in VP1 in the amino acids 20-40. In flavivirus, it is situated about 80 amino acids from the transmembrane region of the E-glucoprotein. In both cases, the sequence participates in interactions with the outer membrane of the host cell. In both cases, the sequence is also concealed to antibodies during part of the replication cycle of the virus, but becomes accessible to them, for instance when the
virus has come into contact with the outer membrane of the cell. Thus, the peptides according to the present
invention can be considered to belong to a previously unknown class of sequences having a common structure and function. Although the peptides can be used for diagnosing diseases caused by both picornavirus and flavivirus, the peptides can, because of their common origin, structure and function, however with a certain, appropriate
variation of the amino acids, be comprised by the same inventive concept. Many or all of the peptides, preferably 3-4, according to the present invention can be included in one and the same assay for diagnosing different
picornavirus- and flavivirus-induced diseases.
As to the presence of the peptides according to the present invention in vaccine compositions, it may initially be stated that the above-mentioned natural basic sequence is included in a region where it has earIler been demonstrated that peptides give rise to neutralising anti¬bodies in rabbit immunisation. In these experiments, however, the peptides according to the present invention were not used, but yet closely related peptide sequences. The evolutionary conservation of said basic sequence confers e.g. the advantage of producing a vaccine inhibiting infection involving many different cold viruses.
As to peptides deriving from flavivirus, the inventor, together with Dr Vincent Deubel at the Arbovirus laboratory at the Pasteur Institute in Paris, has tested the ability of previously known monoclonal antibodies having a virus-neutralising effect, of binding to the
peptides according to the present invention. One of them, lamely peptide (f) directed against Denguevirus, was found, for instance, to strongly bind to a peptide
containing the Dengue variant of the common basic
structure. Since the ability of producing neutralising antibodies is one of the characteristics required of a vaccine, it must be considered highly likely that the peptides according to the present invention are usable as
antigens in vaccine compositions against the above-mentioned picornavirus- and/or flavivirus-induced diseases.
Table 1 refers to the alignment of some different viral amino acid sequences from the region of similarity with HIV-1 p17.
Blomberg, I. Nilsson and M. Andersson. 1983. Viral antibody screening system that uses a standardized single dilution immunoglobulin 6 enzyme immunoassay with multiple antigens. J. Clin. Microbiol. 17:1081-1091.)
If antibodies belonging to the IgM class and reactive with at least one of the picornaviral and/or flaviviral peptides described in the present invention are detected in one or more sera from a patient, then the patient is likely to suffer from a disease caused by a picornavirus and/or a flavivirus.
The peptides according to the present invention can further be used as a supplementary test during the
investigation of an antibody reaction with HIV-1 p17. If the anti-p17 reaction can be abrogated by preabsorption or competition with one of the peptides according to the present invention, it is unlikely that the anti-p17 reaction is caused by antibodies to a picornavirus and/or flavivirus.
The as yet unpublished Swedish patent application 8903985-3, filed on November 27, 1989, also by Replico AB, describes new peptides, diagnostic antigens containing said peptides and having the ability of binding to anti¬bodies which have a binding affinity for compounds containing an amino acid sequence corresponding to an epitope or a cluster of epitopes of HIV-1 p17, and a method of discriminating between a false and true diagnosed HIV-1 positive serum sample using an immunoassay. The technical background, proper definitions, and some of the methods used in connection with the use of the peptides according
to the present invention in the p17 area are described in said Swedish patent application.
After the introduction of large-scale HIV-1 antibody testing, it has been observed that a small portion of sera from humans unlikely to be HIV-1 infected contains antibodies to one or some HIV-1 proteins, mostly derived from the gag part of the molecule. Such reactivities may give rise to HIV-1 electrophoretic immunoblot patterns which are hard to interpret. One of the most common types of such HIV-1 EIB reactivities is characterized by a reactivity with HIV-1 p17, but with no other HIV-1 protein. The reactivity with p17 peptides in sera from healthy Swedes which had the p17 pattern of serological reactivity has been studied. By direct binding and absorption experiments it has been shown that, in contrast to EIB confirmed HIV-1 antibody positive sera, the p17 positive sera reacted with peptides from the C-terminus of p17. It has furthermore been shown that they contain a stretch highly similar to a conserved sequence from the N-terminus of VP1 of some enteroviruses, and to a lesser extent, flaviviruses.
Brief description of the drawings
Figure 1 shows absorption of five p17 positive sera with resin without peptide, resin with HIV-1 gag 118-140, resin with HTLV-I gag 111-130 (the C-terminus of HTLV-I), and resin with Coxsackie B1 VP125-53. The intensity of the p17 band in EIB (y axis) was measured with a
densitometer.
Figure 2 shows the serological reactivity of a peptide derived from Coxsackie B1 VP1 25-53 with
a/ acute and convalescent phase sera from five cases of aseptic meningitis with significant Coxsackie CF titre rises,
b/ 10 p17 reactive sera,
c/ 19 HIV seronegative blood donors and
d/ 6 confirmed HIV-1 antibody positive sera.
Experiment with a Coxsackie B1 VPl derived peptide
A peptide from amino acids 25-53 of the Coxsackie B1 VP1 sequence (Iizuka, N. , S. Kuge and A. Nomoto. 1987.
Complete nucleotide sequence of the genome of Coxsackievirus B1. Virology 156:64-73.) was synthesized, and its ability to absorb p17 antibodies was compared with that of HIV-1 hxb2 gag 118-140 (Fig. 1). In five out of five sera tested, this peptide in resin-bound form absorbed out all p17 EIB reactivity. HIV-1 hxb2 gag 118-140 also absorbed these antibodies, but less completely. Absorption with resin alone, or with HTLV-I gag 111-130 did not affect the p17 EIB reactivity. The p17 reactive antibodies in these sera thus must bind to epitopes simulated by the resinbound Coxsackie-derived peptide. The peptide was present in vast molar excess compared to antibodies, thus favouring absorption also of low-affinity antibodies.
The reactivity of p17-derived peptides was compared with that of a Coxsackie B1-derived peptide. 10 p17 positive sera, 19 HIV seronegative blood donors, 6 sera from confirmed HIV-1 seropositive persons (1 adult and 5 children, aged 1-7), and acute and convalescent sera from six patients with aseptic meningitis with significant (at least fourfold) titre rises in complement fixation antibody tests against Coxsackie B1-B6 antigen were analyzed.
As to antibody activity against the Coxsackie peptide among the p17 reactive sera diluted 1/200, it was found that they did not react significantly more than blood donor sera (Fig 2). This may indicate that the Coxsackie peptide, when absorbed to plastic, does not assume a conformation suitable for binding of p17 reactive antibodies, or that it can bind many other antibodies, which obscures a possible correlation. Six HIV-1 confirmed positive sera with clear p17 bands reacted weakly. Five of the sera were selected from children, to reduce the likelihood of previous exposure to a Coxsackie-like virus. Thus, there was no cross-reactivity of p17 antibodies arising during HIV-1 infection to the Coxsackie peptide.
Finally, six serum pairs were tested from patients with aseptic meningitis who had significant titre rises in the complement fixation test with Coxsackie B1-B6 antigen. It was found that five exhibited clear rises in absorbance difference and one reacted strongly on both sera (Fig. 2). A CF antibody titre rise in this system indicates an enterovirus infection, not necessarily with Coxsackie Bl. When the same sera were tested at a dilution of 1/50, almost all reacted strongly (not shown), attesting to the high antigenicity and frequent recognition of this peptide sequence. The Coxsackie peptide may then be a group-reactive reagent suitable for serological diagnosis of
enterovirus infections. The cross-reaction between the Coxsackie B1 VP1 peptide and HIV-1 hxb2 p17 thus was unidirectional, from the enterovirus to HIV-1, but not vice versa. Antibody reactions with the Coxsackie peptide were very common in Swedish sera diluted 1/50. Only a few of them can bind also to HIV-1 p17 in EIB.
The immunoassays used are described in the Swedish patent application above. Coxsackie antibodies were measured, by titration in standard microtitre complement fixation antibody tests with Coxsackie B1, B2, B3, B4, B5, and B6 antigens.
The diagnostic antigens according to the present invention can be utilized in methods for the same purpose as the claimed use of said diagnostic antigens.
Claims
1. Peptides of the formula
a) H-X-R1-Ala-Y1-Glu-Thr-Gly-His-Thr-Ser-Gln- Val-R2-X-Z, wherein Y1 is Ala or Val,
b) H-X-R1-Ala-Y1-Glu-Thr-Gly-Ala-Thr-Asn-Pro- Leu-R2-X-Z, wherein Y1 is Ala or Val,
c) H-X-R1-Ala-Ala-Glu-Thr-Gly-His-Thr-Ser-Y1- Val-R2-X-Z, wherein Y1 is Ser or Asn,
d) H-X-R1-Y1-Asp-Thr-Gly-His-Gly-Thr-Val-Y2-R2- X-Z, wherein Y1 is Ala or Thr and Y2 is Val or Ile,
e) H-X-R1-Thr-Asp-Y1-Gly-His-Asp-Thr-Val-Y2-R2- X-Z, wherein Y1 is Ser or Thr and Y2 is Ile or Val,
and
f) H-X-R1-Ala-Glu-Thr-Gln-Y1-Gly-Thr-Y2-Val-R2- X-Z, wherein Y1 is His or Tyr and Y2 is Ile or Thr,
in which one X represents a chemical bond and the other X represents a chemical bond or a coupling-facilitating amino acid sequence, R 1 and R2 represent optional amino acid residues, wherein R 1 and R2 together represent at most 25 amino acid residues, and Z represents -NH2 or -OH.
2. Peptides according to claim 1, wherein the
coupling-facilitating amino acid sequence represents at least 4, preferably 8, amino acid residues, which are each selected from the group consisting of -Thr- and -Ser-, and R 1 and R2 together preferably represent at most 20 amino acid residues.
3. A diagnostic antigen having the ability to detect antibodies against at least one type of picornavirus and flavivirus in sera, and/or having the ability of binding to antibodies with a binding affinity for compounds containing an amino acid sequence corresponding to an epitope or cluster of epitopes of HIV-1 p17, c h a r a c t e r i s e d in that it mainly comprises an antigen selected from the peptides according to claim 1 and antigenic parts thereof.
4. Use of a diagnostic antigen according to claim 3 for the diagnosis of Infections caused by picornaviruses and/or flaviviruses, wherein a diagnostic antigen having the ability to detect antibodies against at least one type of picornavirus and flavivirus is added to a serum from a subject suspected to have a recent or previous picorna-virus and/or flavivirus infection, and possible antigen/antibody complexes formed are detected using an immunoassay, the diagnosis of said recent or previous infection or infections caused by picornavirus and/or flavivirus being established based either upon demonstration of antibodies in a single serum or upon a comparison of the amounts of antibodies detected in both acute and convalescent sera, and if said amount in the convalescent serum is significantly larger than that in the acute serum, the subject donating the serum is likely to suffer from a picorna- and/or flavivirus infection, wherein the antigen containing the peptide
a) H-X-R1-Ala-Y1-Glu-Thr-Gly-His-Thr-Ser-Gln- Val-R2-X-Z, wherein Y1 is Ala or Val, is primarily used for diagnosis of diseases caused by Coxsackievirus,
b) H-X-R1-Ala-Y1-Glu-Thr-Gly-Ala-Thr-Asn-Pro- Leu-R2-X-Z, wherein Y1 is Ala or Val, is primarily used for diagnosis of diseases caused by poliovirus,
c) H-X-R1-Ala-Ala-Glu-Thr-Gly-His-Thr-Ser-Y1- Val-R 2-X-Z, wherein Y1 is Ser or Asn, is primarily used for diagnosis of diseases caused by rhinovirus,
d) H-X-R1-Y1-Asp-Thr-Gly-His-Gly-Thr-Val-Y2-R2- X-Z, wherein Y1 is Ala or Thr and Y2 is Val or Ile, is primarily used for diagnosis of diseases caused by yellow fever virus and Japanese encephalitis virus,
e) H-X-R1-Thr-Asp-Y1-Gly-His-Asp-Thr-Val-Y2-R2- X-Z, wherein Y1 is Ser or Thr and Y2 is Ile or Val, is primarily used for diagnosis of diseases caused by TBE-virus,
and
f) H-X-R1-Ala-Glu-Thr-Gln-Y1-Gly-Thr-Y2-Val-R2- X-Z, wherein Y1 is His or Tyr and Y2 is Ile or Thr, is primarily used for diagnosis of diseases caused by Dengue- and rhinovirus, in which one X represents a chemical bond and the other X represents a chemical bond or a coupling-facilitating amino acid sequence, R 1 and R2 represent optional amino acid residues, wherein R 1 and R2 together represent at most 25 amino acid residues, and Z represents -NH2 or -OH.
5. Use of a diagnostic antigen according to claim 3 for discriminating between a false and true diagnosed HIV-1 positive serum sample, which has first been diagnosed as positive in a standard HIV-1 antibody screening EIA test and then found to exhibit a p17 pattern of serological activity in an electrophoretic immunoblot assay, wherein at least one diagnostic antigen having the ability of binding to antibodies which have a binding affinity for compounds containing an amino acid sequence corresponding to an epitope or cluster of epitopes of HIV-1 p17,
optionally coupled to a carrier, is added to said serum sample, and possible antigen/antibody complexes formed are detected using an immunoassay, the discrimination being established such that said serum sample is false HIV-1 positive if said complexes are detected, and true HIV-I positive if said complexes are not detected.
6. Use according to claims 4 and 5, c h a r a c t e r i s e d in that the immunoassay for diagnosis of diseases caused by picornavirus and/or flavivirus and for detection of said antibody/antigen complex, respectively, is an enzyme immunoassay (EIA), radioimmuno assay (RIA), immunoassay involving metal labelling, fluorescence immunoassay (FIA) or an immunoassay in which the peptide is soluble and inhibits another reaction.
7. Use according to claims 4 and 5, c h a r a c t e r i s e d in that the carrier is a resin, microplate, plastic surface, gel or matrix.
8. Use according to claims 4-7, c h a r a c t e r i s e d in that in the diagnosis and discrimination use is simultaneously made of many or all, preferably 3-4, of the diagnostic antigens according to claim 3.
9. A vaccine composition, c h a r a c t e r i s e d in that it comprises as an immunizing component, at least one antigen selected from at least one peptide from the group consisting of
a) H-X-R1-Ala-Y1-Glu-Thr-Gly-His-Thr-Ser-Gln- Val-R2-X-Z, wherein Y1 is Ala or Val,
b) H-X-R1-Ala-Y1-Glu-Thr-Gly-Ala-Thr-Asn-Pro- Leu-R2-X-Z, wherein Y1 is Ala or Val,
c) H-X-R1-Ala-Ala-Glu-Thr-Gly-His-Thr-Ser-Y1- Val-R2-X-Z, wherein Y1 is Ser or Asn,
d) H-X-R1-Y1-Asp-Thr-Gly-His-Gly-Thr-Val-Y2-R2- X-Z, wherein Y1 is Ala or Thr and Y2 is Val or Ile,
e) H-X-R1-Thr-Asp-Y1-Gly-His-Asp-Thr-Val-Y2-R2- X-Z, wherein Y1 is Ser or Thr and Y2 is Ile or Val, and
f) H-X-R1-Ala-Glu-Thr-Gln-Y1-Gly-Thr-Y2-Val-R2- X-Z, wherein Y1 is His or Tyr and Y2 is Ile or Thr,
in which one X represents a chemical bond and the other X represents a chemical bond or a coupling-facilitating amino acid sequence, R 1 and R2 represent optional amino acid residues, wherein R 1 and R2 together represent at most 25 amino acid residues, and Z represents -NH- or -OH, and antigenic parts thereof, together with a non-toxic pharmaceutically acceptable carrier and/or diluent.
10. A vaccine composition according to claim 9, c h a r a c t e r i s e d in that it comprises said picorna- and/or flavivirus antigen or antigens in an amount effective to protect a subject from diseases caused by picornaviruses and/or flaviviruses.
11. A vaccine composition according to claim 9, c h a r a c t e r i s ed in that it further comprises an antigen adjuvant in an amount which together with an amount of said picornavirus and/or flavivirus antigen or is effective to protect a subject from diseases caused by picornaviruses and/or flaviviruses.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU84002/91A AU649473B2 (en) | 1990-08-16 | 1991-08-16 | Enterovirus peptides |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9002671A SE470074B (en) | 1990-08-16 | 1990-08-16 | Method for diagnosis of picorene and / or flavivirus infection, peptides, diagnostic antigens and vaccine composition with these peptides |
| SE9002671-7 | 1990-08-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1992003475A1 true WO1992003475A1 (en) | 1992-03-05 |
Family
ID=20380170
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/SE1991/000542 WO1992003475A1 (en) | 1990-08-16 | 1991-08-16 | Enterovirus peptides |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP0546031A1 (en) |
| AU (1) | AU649473B2 (en) |
| SE (1) | SE470074B (en) |
| WO (1) | WO1992003475A1 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6689879B2 (en) | 1998-12-31 | 2004-02-10 | Chiron Corporation | Modified HIV Env polypeptides |
| US7211659B2 (en) | 2001-07-05 | 2007-05-01 | Chiron Corporation | Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof |
| US7282364B2 (en) | 2001-08-31 | 2007-10-16 | Novartis Vaccines And Diagnostics, Inc. | Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof |
| WO2014140166A2 (en) * | 2013-03-15 | 2014-09-18 | Glaxosmithkline Biologicals S.A. | Vaccine |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0106837A2 (en) * | 1982-10-05 | 1984-04-25 | IMMUNO Aktiengesellschaft für chemisch-medizinische Produkte | Use of peptides |
| WO1986006414A1 (en) * | 1985-04-29 | 1986-11-06 | Genetic Systems Corporation | Synthetic antigens for the detection of aids-related disease |
| WO1988003032A1 (en) * | 1986-10-27 | 1988-05-05 | Fournier Maurielle J | Diagnosis of and vaccine for japanese encephalitis virus and related viruses |
| EP0284791A1 (en) * | 1987-03-20 | 1988-10-05 | IMMUNO Aktiengesellschaft | DNA and RNA molecules of the western-subtype TBE virus, polypeptides coded by these molecules and their use |
| US4810492A (en) * | 1986-06-05 | 1989-03-07 | The Research Foundation For Microbial Diseases Of Osaka University | Flavivirus antigen |
| GB2209764A (en) * | 1987-09-16 | 1989-05-24 | Nippon Zeon Co | Recombinant vaccinia virus |
| EP0358485A2 (en) * | 1988-09-08 | 1990-03-14 | The Wellcome Foundation Limited | Human rhinovirus peptides |
-
1990
- 1990-08-16 SE SE9002671A patent/SE470074B/en not_active IP Right Cessation
-
1991
- 1991-08-16 AU AU84002/91A patent/AU649473B2/en not_active Ceased
- 1991-08-16 EP EP91915656A patent/EP0546031A1/en not_active Withdrawn
- 1991-08-16 WO PCT/SE1991/000542 patent/WO1992003475A1/en not_active Application Discontinuation
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0106837A2 (en) * | 1982-10-05 | 1984-04-25 | IMMUNO Aktiengesellschaft für chemisch-medizinische Produkte | Use of peptides |
| WO1986006414A1 (en) * | 1985-04-29 | 1986-11-06 | Genetic Systems Corporation | Synthetic antigens for the detection of aids-related disease |
| US4810492A (en) * | 1986-06-05 | 1989-03-07 | The Research Foundation For Microbial Diseases Of Osaka University | Flavivirus antigen |
| WO1988003032A1 (en) * | 1986-10-27 | 1988-05-05 | Fournier Maurielle J | Diagnosis of and vaccine for japanese encephalitis virus and related viruses |
| EP0284791A1 (en) * | 1987-03-20 | 1988-10-05 | IMMUNO Aktiengesellschaft | DNA and RNA molecules of the western-subtype TBE virus, polypeptides coded by these molecules and their use |
| GB2209764A (en) * | 1987-09-16 | 1989-05-24 | Nippon Zeon Co | Recombinant vaccinia virus |
| EP0358485A2 (en) * | 1988-09-08 | 1990-03-14 | The Wellcome Foundation Limited | Human rhinovirus peptides |
Non-Patent Citations (21)
| Title |
|---|
| Advances in veterinary science and comparative medicine, Vol. 33, 1989 J M HOGLE et al.: "Poliovirus: Three-dimensional Structure of a Viral Antigen", see page 65 - page 91, see in particular pages 72-73 and 80-81. * |
| Aids, Vol. 3, No. 12, 1989 R B FERNS et al.: "Epitope location of 13 anti-gag HIV-1 monoclonal antibodies using oligopeptides and their cross reactivity with HIV-2", see page 829 - page 834, see table 3. * |
| Am.J.Trop.Med.Hyg., Vol. 40, No. 6, 1989 B L INNIS et al.: "Identification of continuous epitopes of the envelope glycoprotein of dengue type 2 virus", see page 676 - page 687, see fig 1, hexapeptides 310-330 and Table 2, domain 17. * |
| Arch Virol, Vol. 105, 1989 J.G. AASKOV et al.: "Serologically defined linear epitopes in the envelope protein of dengue 2", see page 209 - page 221; figure 1. * |
| CHEMICAL ABSTRACTS, Volume 113, No. 19, 5 November 1990, (Columbus, Ohio, US), HINKULA J et al.: "Epitope mapping of the HIV-1 gag region with monoclonal antibodies", see page 519, Abstract 169943x, & Mol.Immunol. 1990, 27(5), 395-403. * |
| Dialog Information Services, File 155, Medline 66-91, Dialog Accession No. 06304270, HALL RA et al.: "An enzyme immunoassay to detect Australian flaviviruses and indentify the encephalitic subgroup using monoclonal antibodies", Immunol Cell Biol Feb 1987, 65 (Pt 1) p 103-10. * |
| Dialog Information Services, File 155, Medline 66-91, Dialog Accession No. 06323973, SRIVASTAVA AK et al.: "Antigenicity of Japanese encephalitis virus envelope glycoproteinV3 (E) and its cyanogen bromide cleaved fragments examined by monoclonal antibodies and western blotting", Arch Virol 1987, 96 (1-2) p * |
| Dialog Information Services, File 155, Medline 66-91, Dialog Accession No. 07059248, KURANE I et al.: "Dengue virus-specific human T cell clones. Serotype crossreactive proliferation, interferon gamma production, and cytotoxic activity", J Exp Med Sep 1 1989, 170 (3) p 763-75. * |
| Dialog Information Services, File 155, Medline 83-91, Dialog Accession No. 04796728, HEINZ FX et al.: "Monoclonal antibodies to the structural glycoprotein of tick-borne encephalitis virus", Infect Immun Sep 1982, 37 (3) p 869-74. * |
| Immunology, Vol. 67, 1989 T. MATHIESEN et al.: "Mapping of IGG subclass and T-cell epitopes on HIV proteins by synthetic peptides", see page 453 - page 459, see page 455, peptides 29 and 30. * |
| Infection and Immunity, Vol. 37, No. 3, 1982 FRANZ X. HEINZ et al.: "Monoclonal Antibodies to the Structural Glycoprotein of Tick-Borne Encephalitis Virus", see page 869 - page 874. * |
| Journal of Acquired Immune Deficiency Syndromes, Vol. 4, 1989, B. WAHREN, et al.: "HIV-1 peptides induce a proliferative response in lymphocytes from infected persons", see page 448 - page 456, see page 449, peptide 30, table 2, peptides 235-237. * |
| Journal of Virology, Vol. 63, No. 2, 1989 C W MANDL et al.: "Antigenic structure of the flavivirus envelope protein E at the molecular level, using tick-borne encephalitis virus as a model", see fig 1 and tables 2 and 3, fragment IRF1. * |
| Journal of Virology, Vol. 63, No. 8, August 1989 M NIEDRIG et al.: "Epitope Mapping of Monoclonal Antibodies against Human Immunodeficiency Virus Type 1 Structural Proteins by Using Peptides", see page 3525 - page 3528, see table 1. * |
| Journal of Virology, Vol. 64, No. 2, 1990 M ROIVAINEN et al.: "Improved distribution of Antigenic Site Specificity of Poliovirus-Neutralizing Antibodies Induced by a Protease-Cleaved Immunogen in Mice", see page 559 - page 562. * |
| Journal of Virology, Vol. 64, No. 5, May 1990, C E FRICKS et al.: "Cell-Induced Conformational Change in Poliovirus:Externalization of the Amino Terminus of VPI Is Responsible for Liposome Binding", see page 1934 - page 1945, see page 1944, last paragraph. * |
| Nature, Vol. 317, September 1985 M G ROSSMANN et al.: "Structure of a human common cold virus and functional relationship to other picornaviruses", see page 145 - page 153; figure 4. * |
| Proc. Natl. Acad. Sci., Vol. 82, February 1985, M. CHOW et al.: "Synthetic peptides from four seprate regions of the poliovirus type 1 capsid protein VP1 induce neutralizing antibodies", see page 910 - page 914. * |
| Virology, Vol. 174, 1990 A G PLETNEV et al.: "Nucleotide Sequence of the Genome and Complete Amino Acid Sequence of the Polyprotein of Tick-Borne Encephalitis Virus", see page 250 - page 263; figure 4. * |
| Virology, Vol. 177, 1990 J T ROEHRIG et al.: "Antibodies to Dengue 2 Virus E-Glycoprotein Synthetic Peptides Identify Antigenic Conformation", see page 668 - page 675, see peptide 07 in tables 1 and 3. * |
| Virology, Vol. 180, 1991 M ROIVAINEN et al.: "Antigenic Regions of Poliovirus Type 3/Sabin Capsid Proteins Recognized by Human Sera in the Peptide Scanning Technique", see page 99 - page 107, see in particular page 100 (peptides 13 and 14). * |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6689879B2 (en) | 1998-12-31 | 2004-02-10 | Chiron Corporation | Modified HIV Env polypeptides |
| US7211659B2 (en) | 2001-07-05 | 2007-05-01 | Chiron Corporation | Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof |
| US8133494B2 (en) | 2001-07-05 | 2012-03-13 | Novartis Vaccine & Diagnostics Inc | Expression cassettes endcoding HIV-1 south african subtype C modified ENV proteins with deletions in V1 and V2 |
| US9598469B2 (en) | 2001-07-05 | 2017-03-21 | Novartis Vaccines And Diagnostics, Inc. | HIV-1 south african subtype C env proteins |
| US7282364B2 (en) | 2001-08-31 | 2007-10-16 | Novartis Vaccines And Diagnostics, Inc. | Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof |
| WO2014140166A2 (en) * | 2013-03-15 | 2014-09-18 | Glaxosmithkline Biologicals S.A. | Vaccine |
| WO2014140166A3 (en) * | 2013-03-15 | 2014-11-20 | Glaxosmithkline Biologicals S.A. | Vaccine |
| BE1022174B1 (en) * | 2013-03-15 | 2016-02-24 | Glaxosmithkline Biologicals S.A. | VACCINE |
| US10058603B2 (en) | 2013-03-15 | 2018-08-28 | Glaxosmithkline Biologicals S.A. | Vaccine |
| US10493145B2 (en) | 2013-03-15 | 2019-12-03 | Glaxosmithkline Biologicals Sa | Immunogenic rhinovirus peptides |
Also Published As
| Publication number | Publication date |
|---|---|
| SE9002671D0 (en) | 1990-08-16 |
| AU8400291A (en) | 1992-03-17 |
| SE470074B (en) | 1993-11-01 |
| AU649473B2 (en) | 1994-05-26 |
| SE9002671L (en) | 1992-02-17 |
| EP0546031A1 (en) | 1993-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2763215B2 (en) | Synthetic peptides specific for detecting antibodies to HCV, diagnosing HCV infection and its prevention as a vaccine | |
| KR940000755B1 (en) | Synthetic peptides specific for the detection of antibodies to hcv | |
| JP3514680B2 (en) | Hepatitis C virus (HCV) polypeptide | |
| JP3156200B2 (en) | New HCV isolate | |
| CN1360678B (en) | Method for early detection of flaviviruses using NS1 glycoprotein and application thereof | |
| Zhao et al. | A comprehensive study of neutralizing antigenic sites on the hepatitis E virus (HEV) capsid by constructing, clustering, and characterizing a tool box | |
| US7179470B2 (en) | Hepatitis-C virus testing | |
| JPH04253998A (en) | C-type hepatitis assay | |
| Cello et al. | Identification of group-common linear epitopes in structural and nonstructural proteins of enteroviruses by using synthetic peptides | |
| Lennette et al. | Picornaviridae: the enteroviruses (polioviruses, coxsackieviruses, echoviruses) | |
| CN105418738A (en) | A-type antigen polypeptide, fusion antigen polypeptide and vaccine of foot and mouth disease virus | |
| Melnick | Poliovirus and other enteroviruses | |
| CN113607952B (en) | African swine fever virus blocking ELISA antibody detection kit and preparation method and application thereof | |
| EP0828756A2 (en) | Diagnosis of, and vaccination against, a positive stranded rna virus using an isolated, unprocessed polypeptide | |
| JPH06510861A (en) | Hepatitis C assay | |
| Yeung et al. | The cell attachment proteins of type 1 and type 3 reovirus are differentially susceptible to trypsin and chymotrypsin | |
| US5824506A (en) | Dengue virus peptides and methods | |
| AU649473B2 (en) | Enterovirus peptides | |
| US5843450A (en) | Hepatitis GB Virus synthetic peptides and uses thereof | |
| Qi et al. | Synthesis and application of hepatitis E virus peptides to diagnosis | |
| Kurstak et al. | Enzyme immunoassays and related procedures in diagnostic medical virology | |
| RU2811996C1 (en) | Test system for determining titer of antibodies against 146s particles of foot-and-mouth disease virus genotype sat-2/iv using elisa liquid-phase | |
| Samuelson et al. | Enterovirus IgG ELISA using synthetic peptides as antigens | |
| Reigel et al. | Cross-reactions of immunoglobulin M and G antibodies with enterovirus-specific viral structural proteins | |
| WO2005047308A2 (en) | Peptide-based diagnostic reagents for sars |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AT AU BB BG BR CA CH CS DE DK ES FI GB HU JP KP KR LK LU MC MG MW NL NO PL RO SD SE SU US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU ML MR NL SE SN TD TG |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1991915656 Country of ref document: EP |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| WWP | Wipo information: published in national office |
Ref document number: 1991915656 Country of ref document: EP |
|
| NENP | Non-entry into the national phase |
Ref country code: CA |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 1991915656 Country of ref document: EP |